BioOutsource Expands ADC Characterisation Capabilities

BioOutsource Logo

A global leader in ADC characterisation, BioOutsource, partners with Glythera.
Exhibits at World ADC Summit in Frankfurt.

Glasgow Scotland, UK, February 18, 2014 / B3C newswire / – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has amplified its position as a global leader in Antibody Drug Conjugates (ADC) characterisation and are pleased to announce a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne that specializes in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.

“Building on our position as a leader in biological characterisation of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products.  We are delighted to partner with Glythera to characterise their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource CSO, Daniel Galbraith.

Chief Operating Officer at Glythera Dr David Simpson, highlighted the value of the collaboration, “we are delighted to have the opportunity to work with BioOutsource on their ADC characterisation as it is an area where our linker technologies offer significant benefits.  This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”

BioOutsource has also announced that it will be exhibiting at the World ADC Summit, 17-20 February in Frankfurt, in partnership with Aptuit, Glasgow, a pharmaceutical services company, and with support from Scottish Development International (SDI).

“We are eagerly anticipating exhibiting at the World ADC Summit in Frankfurt,” continued Dr. Galbraith. “In partnership with Aptuit and with generous support from Scottish Development International, we welcome the opportunity to demonstrate our expertise in ADC characterisation.”

More information on the World ADC Summit is available at

About BioOutsource Ltd
BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & Biosimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s increasingly preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally. 

About Glythera Ltd
Glythera is a biotechnology company specializing in the development of next generation therapeutics through the application of its linker and stable glycan technologies PermaLink™ and PermaCarb™. Our technologies offer improved stability, bioavailability and efficiency in oncology and therapeutics applications. To find out more about Glythera and applications of PermaLink™ and PermaCarb™ please visit or contact us via This email address is being protected from spambots. You need JavaScript enabled to view it.


For BioOutsource:

Gemma Fulton
Sales and Marketing Associate
BioOutsource, Ltd.
+ 44 (0) 141 946 4222 
This email address is being protected from spambots. You need JavaScript enabled to view it.


Bill Douglass
Gotham Communications, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.